. "1" . "5"^^ . . "Neurologick\u00E9 m\u011Bkk\u00E9 p\u0159\u00EDznaky u schizofrenie"@cs . . "RIV/00216224:14110/04:00010193!RIV08-MSM-14110___" . "19-23" . "Pr\u00E1ce shrnuje problematiku neurologick\u00FDch m\u011Bkk\u00FDch p\u0159\u00EDznak\u016F (NSS) u schizofrenn\u00EDho onemocn\u011Bn\u00ED. Zvl\u00E1\u0161tn\u00ED pozornost je v\u011Bnov\u00E1na NSS u prvn\u00EDch epizod schizofrenie. Jsou uv\u00E1d\u011Bny mo\u017Enosti jejich m\u011B\u0159en\u00ED. U psychiatrick\u00E9 populace je preferov\u00E1no pou\u017Eit\u00ED \u0161k\u00E1ly Neurological Examination Scale (NES). NSS se vyskytuje u schizofrenn\u00ED poruchy v\u00FDznamn\u011B \u00EDce \u010Dasto ne\u017E u zdrav\u00E9 populace. Rozmez\u00E9 ud\u00E1van\u00E9ho v\u00FDskytu je \u0161irok\u00E9 a souvis\u00ED s pou\u017Eitou metodou a stanoven\u00EDm krit\u00E9ri\u00ED pozitivity. Jsou p\u0159\u00EDtomny ji\u017E v inici\u00E1ln\u00ED f\u00E1zi onemocn\u011Bn\u00ED. Nesouvisej\u00ED v\u00FDznamn\u011Bji s medikac\u00ED, i kdy\u017E tato m\u016F\u017Ee \u010D\u00E1ste\u010Dn\u011B ovlivnit jejich prevalenci. V\u00FDskyt NSS nejv\u00EDce koreluje s kognitivn\u00ED dysfunkc\u00ED a negativn\u00ED symptomatologi\u00ED. Jedinci s v\u00FDskytem NSS maj\u00ED hor\u0161\u00ED progn\u00F3zu. Stanoven\u00ED NSS v inici\u00E1ln\u00ED f\u00E1zi nemoci m\u016F\u017Ee p\u0159isp\u011Bt k identifikaci subjekt\u016F se \u0161patnou progn\u00F3zou, kte\u0159\u00ED by mohli profitovat z \u010Dasn\u00E9 intervence a c\u00EDlen\u00E9 farmakoterapie nap\u0159\u00EDklad n\u011Bkter\u00FDmi atypick\u00FDmi antipsychotiky. Hodnocen\u00ED by m\u011Blo b\u00FD\u0159 jednotn\u00E9 a oboustrann\u00E9. V budoucnosti bude vhodn\u00E9 i"@cs . "RIV/00216224:14110/04:00010193" . "1212-0383" . "neurological soft signs; schizophrenia; first-episode schizophrenia; symptoms; outcome; cognitive dysfunction"@en . . "Z(MSM 141100001)" . "Pr\u00E1ce shrnuje problematiku neurologick\u00FDch m\u011Bkk\u00FDch p\u0159\u00EDznak\u016F (NSS) u schizofrenn\u00EDho onemocn\u011Bn\u00ED. Zvl\u00E1\u0161tn\u00ED pozornost je v\u011Bnov\u00E1na NSS u prvn\u00EDch epizod schizofrenie. Jsou uv\u00E1d\u011Bny mo\u017Enosti jejich m\u011B\u0159en\u00ED. U psychiatrick\u00E9 populace je preferov\u00E1no pou\u017Eit\u00ED \u0161k\u00E1ly Neurological Examination Scale (NES). NSS se vyskytuje u schizofrenn\u00ED poruchy v\u00FDznamn\u011B \u00EDce \u010Dasto ne\u017E u zdrav\u00E9 populace. Rozmez\u00E9 ud\u00E1van\u00E9ho v\u00FDskytu je \u0161irok\u00E9 a souvis\u00ED s pou\u017Eitou metodou a stanoven\u00EDm krit\u00E9ri\u00ED pozitivity. Jsou p\u0159\u00EDtomny ji\u017E v inici\u00E1ln\u00ED f\u00E1zi onemocn\u011Bn\u00ED. Nesouvisej\u00ED v\u00FDznamn\u011Bji s medikac\u00ED, i kdy\u017E tato m\u016F\u017Ee \u010D\u00E1ste\u010Dn\u011B ovlivnit jejich prevalenci. V\u00FDskyt NSS nejv\u00EDce koreluje s kognitivn\u00ED dysfunkc\u00ED a negativn\u00ED symptomatologi\u00ED. Jedinci s v\u00FDskytem NSS maj\u00ED hor\u0161\u00ED progn\u00F3zu. Stanoven\u00ED NSS v inici\u00E1ln\u00ED f\u00E1zi nemoci m\u016F\u017Ee p\u0159isp\u011Bt k identifikaci subjekt\u016F se \u0161patnou progn\u00F3zou, kte\u0159\u00ED by mohli profitovat z \u010Dasn\u00E9 intervence a c\u00EDlen\u00E9 farmakoterapie nap\u0159\u00EDklad n\u011Bkter\u00FDmi atypick\u00FDmi antipsychotiky. Hodnocen\u00ED by m\u011Blo b\u00FD\u0159 jednotn\u00E9 a oboustrann\u00E9. V budoucnosti bude vhodn\u00E9 i" . . "575966" . . . . "14110" . "[C41FBF25D23F]" . "Neurologick\u00E9 m\u011Bkk\u00E9 p\u0159\u00EDznaky u schizofrenie" . . . "\u010Cesk\u00E1 a Slovensk\u00E1 psychiatrie" . "Neurologick\u00E9 m\u011Bkk\u00E9 p\u0159\u00EDznaky u schizofrenie"@cs . "problemns of soft signs i\u00E1n schizophrenia are summarized, special attention is devoted to neurological soft signs (NSS)in the first-episode schizophrenia. Out of many possibilities how to measure NSS, Neurological Evaluation Scale is most commonly used in psychiatric population. NSS are significantly more frequent in patietnes with schizophrenia than innormal population. The range of NSS frequency is broad and related to the metjhods used amd criteria of evaluation. NSS are present in the initial phase of illness. They are not significantly associated with administration of antipsychotics, but antipsychotics can partiallly influence its prevalence. The occurrence of NSS most frequently correlates with cognitive dyfunction and negative symptoms. Patients with NSS have a worse prognosis. The evaluation of NSS in the initial phase of illness can contribute to the identification of subjects with bad prognosis, who, can profit from early intervention and targeted pharmacotherapy ( for example sith some aty"@en . "1"^^ . . . . "\u010Ce\u0161kov\u00E1, Eva" . "Neurologick\u00E9 m\u011Bkk\u00E9 p\u0159\u00EDznaky u schizofrenie" . . "CZ - \u010Cesk\u00E1 republika" . . . "1"^^ . "100" . . . "Neurological soft signs in schizophrenia"@en . "Neurological soft signs in schizophrenia"@en .